{"id":13446,"date":"2022-11-30T11:12:00","date_gmt":"2022-11-30T11:12:00","guid":{"rendered":"https:\/\/www.sygnaturediscovery.com\/?post_type=journal-paper&p=13446"},"modified":"2026-01-30T11:21:26","modified_gmt":"2026-01-30T11:21:26","slug":"discovery-and-optimization-of-potent-and-orally-available-ctp-synthetase-inhibitors-for-use-in-treatment-of-diseases-driven-by-aberrant-immune-cell-proliferation","status":"publish","type":"journal-paper","link":"https:\/\/www.sygnaturediscovery.com\/fr\/journal-paper\/discovery-and-optimization-of-potent-and-orally-available-ctp-synthetase-inhibitors-for-use-in-treatment-of-diseases-driven-by-aberrant-immune-cell-proliferation\/","title":{"rendered":"Discovery and Optimization of Potent and Orally Available CTP Synthetase Inhibitors for Use in Treatment of Diseases Driven by Aberrant Immune Cell Proliferation"},"content":{"rendered":"\n

Andrew Novak, David Laughton, Rebecca Lane, Emma Blackham, Jennifer Thomas, Elli Chatzopoulou, Joseph Wrigglesworth, Abdul Quddus, Saleh Ahmed, David Cousin, Lorna Duffy, Nathalie Dubois, John Unitt, Katalin Orban, Edward Browne, Michelle Ward, David Mycock, Maria Ieva, Nicholas Bland<\/strong>, Pascal George, Timothy Bourne, H\u00e9l\u00e8ne Asnagli, Louise Birchm, Geraint Jones<\/strong><\/p>\n\n\n\n

Abstract<\/strong><\/p>\n\n\n\n

Herein, we report the discovery of a first-in-class chemotype 2-(alkylsulfonamido)thiazol-4-yl)acetamides that act as pan-selective inhibitors of cytidine 5\u2032-triphosphate synthetase (CTPS1\/2), critical enzymes in the de novo<\/em> pyrimidine synthesis pathway. Weak inhibitors identified from a high-throughput screening of 240K compounds have been optimized to a potent, orally active agent, compound 27<\/strong>, which has shown significant pharmacological responses at 10 mg\/kg dose BID in a well-established animal model of inflammation.<\/p>\n\n\n\n

Ref: J Med Chem 2022<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"featured_media":0,"template":"","category":[681,682,679,713],"resource_tag":[],"class_list":["post-13446","journal-paper","type-journal-paper","status-publish","hentry","category-bioscience","category-chemistry","category-computer-aided-drug-design","category-medicinal-chemistry"],"acf":[],"yoast_head":"\nOrally Available CTP Synthetase (CTPS1\/2) Inhibitors<\/title>\n<meta name=\"description\" content=\"A 240K-compound HTS led to first-in-class pan-selective CTPS1\/2 inhibitors; compound 27 was orally active in an animal model of inflammation. Read more.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sygnaturediscovery.com\/fr\/journal-paper\/discovery-and-optimization-of-potent-and-orally-available-ctp-synthetase-inhibitors-for-use-in-treatment-of-diseases-driven-by-aberrant-immune-cell-proliferation\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Orally Available CTP Synthetase (CTPS1\/2) Inhibitors\" \/>\n<meta property=\"og:description\" content=\"A 240K-compound HTS led to first-in-class pan-selective CTPS1\/2 inhibitors; compound 27 was orally active in an animal model of inflammation. Read more.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sygnaturediscovery.com\/fr\/journal-paper\/discovery-and-optimization-of-potent-and-orally-available-ctp-synthetase-inhibitors-for-use-in-treatment-of-diseases-driven-by-aberrant-immune-cell-proliferation\/\" \/>\n<meta property=\"og:site_name\" content=\"Sygnature\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-30T11:21:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/02\/sygnature-hit-to-lead-team-collaboration-scaled.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/journal-paper\\\/discovery-and-optimization-of-potent-and-orally-available-ctp-synthetase-inhibitors-for-use-in-treatment-of-diseases-driven-by-aberrant-immune-cell-proliferation\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/journal-paper\\\/discovery-and-optimization-of-potent-and-orally-available-ctp-synthetase-inhibitors-for-use-in-treatment-of-diseases-driven-by-aberrant-immune-cell-proliferation\\\/\",\"name\":\"Orally Available CTP Synthetase (CTPS1\\\/2) Inhibitors\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\"},\"datePublished\":\"2022-11-30T11:12:00+00:00\",\"dateModified\":\"2026-01-30T11:21:26+00:00\",\"description\":\"A 240K-compound HTS led to first-in-class pan-selective CTPS1\\\/2 inhibitors; compound 27 was orally active in an animal model of inflammation. Read more.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/journal-paper\\\/discovery-and-optimization-of-potent-and-orally-available-ctp-synthetase-inhibitors-for-use-in-treatment-of-diseases-driven-by-aberrant-immune-cell-proliferation\\\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/journal-paper\\\/discovery-and-optimization-of-potent-and-orally-available-ctp-synthetase-inhibitors-for-use-in-treatment-of-diseases-driven-by-aberrant-immune-cell-proliferation\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/journal-paper\\\/discovery-and-optimization-of-potent-and-orally-available-ctp-synthetase-inhibitors-for-use-in-treatment-of-diseases-driven-by-aberrant-immune-cell-proliferation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Discovery and Optimization of Potent and Orally Available CTP Synthetase Inhibitors for Use in Treatment of Diseases Driven by Aberrant Immune Cell Proliferation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"name\":\"Sygnature Discovery\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\"},\"alternateName\":\"Sygnature\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\",\"name\":\"Sygnature Discovery\",\"alternateName\":\"Sygnature\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"width\":1,\"height\":1,\"caption\":\"Sygnature Discovery\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.youtube.com\\\/@sygnature.discovery\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/sygnature-discovery\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Orally Available CTP Synthetase (CTPS1\/2) Inhibitors","description":"A 240K-compound HTS led to first-in-class pan-selective CTPS1\/2 inhibitors; compound 27 was orally active in an animal model of inflammation. Read more.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sygnaturediscovery.com\/fr\/journal-paper\/discovery-and-optimization-of-potent-and-orally-available-ctp-synthetase-inhibitors-for-use-in-treatment-of-diseases-driven-by-aberrant-immune-cell-proliferation\/","og_locale":"fr_CA","og_type":"article","og_title":"Orally Available CTP Synthetase (CTPS1\/2) Inhibitors","og_description":"A 240K-compound HTS led to first-in-class pan-selective CTPS1\/2 inhibitors; compound 27 was orally active in an animal model of inflammation. Read more.","og_url":"https:\/\/www.sygnaturediscovery.com\/fr\/journal-paper\/discovery-and-optimization-of-potent-and-orally-available-ctp-synthetase-inhibitors-for-use-in-treatment-of-diseases-driven-by-aberrant-immune-cell-proliferation\/","og_site_name":"Sygnature","article_modified_time":"2026-01-30T11:21:26+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/02\/sygnature-hit-to-lead-team-collaboration-scaled.webp","type":"image\/webp"}],"twitter_card":"summary_large_image","twitter_misc":{"Estimation du temps de lecture":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/journal-paper\/discovery-and-optimization-of-potent-and-orally-available-ctp-synthetase-inhibitors-for-use-in-treatment-of-diseases-driven-by-aberrant-immune-cell-proliferation\/","url":"https:\/\/www.sygnaturediscovery.com\/fr\/journal-paper\/discovery-and-optimization-of-potent-and-orally-available-ctp-synthetase-inhibitors-for-use-in-treatment-of-diseases-driven-by-aberrant-immune-cell-proliferation\/","name":"Orally Available CTP Synthetase (CTPS1\/2) Inhibitors","isPartOf":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website"},"datePublished":"2022-11-30T11:12:00+00:00","dateModified":"2026-01-30T11:21:26+00:00","description":"A 240K-compound HTS led to first-in-class pan-selective CTPS1\/2 inhibitors; compound 27 was orally active in an animal model of inflammation. Read more.","breadcrumb":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/journal-paper\/discovery-and-optimization-of-potent-and-orally-available-ctp-synthetase-inhibitors-for-use-in-treatment-of-diseases-driven-by-aberrant-immune-cell-proliferation\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sygnaturediscovery.com\/fr\/journal-paper\/discovery-and-optimization-of-potent-and-orally-available-ctp-synthetase-inhibitors-for-use-in-treatment-of-diseases-driven-by-aberrant-immune-cell-proliferation\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/journal-paper\/discovery-and-optimization-of-potent-and-orally-available-ctp-synthetase-inhibitors-for-use-in-treatment-of-diseases-driven-by-aberrant-immune-cell-proliferation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sygnaturediscovery.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Discovery and Optimization of Potent and Orally Available CTP Synthetase Inhibitors for Use in Treatment of Diseases Driven by Aberrant Immune Cell Proliferation"}]},{"@type":"WebSite","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","name":"Sygnature Discovery","description":"","publisher":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization"},"alternateName":"Sygnature","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sygnaturediscovery.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization","name":"Sygnature Discovery","alternateName":"Sygnature","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","width":1,"height":1,"caption":"Sygnature Discovery"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.youtube.com\/@sygnature.discovery","https:\/\/www.linkedin.com\/company\/sygnature-discovery\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/journal-paper\/13446","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/journal-paper"}],"about":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/types\/journal-paper"}],"version-history":[{"count":0,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/journal-paper\/13446\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media?parent=13446"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/category?post=13446"},{"taxonomy":"resource_tag","embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/resource_tag?post=13446"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}